11,250,000 Shares of Common Stock and Pre-Funded Warrants to Purchase 3,750,000 Shares of Common Stock Rezolute, Inc. UNDERWRITING AGREEMENTUnderwriting Agreement • June 14th, 2024 • Rezolute, Inc. • Pharmaceutical preparations • New York
Introductory. Rezolute, Inc., a Nevada corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 11,250,000 shares of its common stock, par value $0.001 per share (the “Common Stock”) and (ii) pre-funded warrants of the Company (in the form attached hereto as Exhibit C) to purchase 3,750,000 shares of Common Stock (the “Pre-Funded Warrants”). The 11,250,000 shares of Common Stock to be sold by the Company are called the “Firm Shares.” As used herein “Warrant Shares” means the shares of Common Stock issuable upon exercise of the Pre-Funded Warrants. In addition, the Company has granted to the Underwriters an option to purchase up to an additional 2,250,000 shares of Common Stock. The additional 2,250,000 shares of Common Stock to be sold by the Company pursuant to such option are called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are c
